ifinatamab deruxtecan
daiichi sankyo
['ds-7300']
the #oncoalerttoptweet #esmo22 day 3 tweet ds-7300, an adc against b7-h3, induced a confirmed response in 10/19 (53%) patients. dor : 5.5 months. update of the subgroup analysis from the phase i/ii study that enrolled 147 patients. best 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??